Opinion
Video
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Science at AACR Aims to Overcome Cancer Care Barriers
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Overweight-to-Obese Trajectory in Adulthood May Raise Ovarian Cancer Risk
5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas